The Road to Leadership in Healthcare Innovation
Georgia is certainly on the pulse of global healthcare now, but its leadership in biosciences did not happen overnight. It has taken years of developing the right combination of infrastructure, logistics and visionary leadership to get the state where it is today.
The state’s foundation in healthcare innovation was established in 1946 when the Communicable Diseases Center (CDC) launched operations in Atlanta to eradicate malaria in the southeastern United States. An effort led by Georgia-native Dr. William H. Foege in the 1970s drove the CDC, now the Center for Disease Control and Prevention, to triumph over small pox. In 1984, the CDC kickstarted its campaigns to tackle HIV/AIDS.
Today, the CDC is a global leader in public health and America’s premier health promotion, prevention and preparedness agency. Its result-driven programs have moved beyond infectious diseases and now include goals to fight cancer, heart-disease and health-related consequences of risky habits such as smoking.
CDC’s initiatives are not the only ones putting Georgia on the map for bio-science and health care innovation. In fact, Georgia’s health IT industry hosts over 200 companies and employs more than 16,000 people. Other state organizations making strides in global health include CARE International,MAP International and the National Health Museum. Additionally, Georgia’s university system is continuously producing research that is breaking ground in healthcare innovation. Georgia Tech and Emory’s nationally-ranked BioMed joint-engineering program and the Morehouse School of Medicine’s Global Healthcare Alliance both play a major role.
According to a recent article in Atlanta Magazine, Georgia’s strategic location and resources such as logistics and infrastructure were also key factors in Baxter International’s decision to build its largest-ever blood plasma manufacturing operation in Covington.
To read more about the healthcare innovations of Georgia-based leaders like the CDC, as well as Baxter’s $1 billion new bioscience plant, view the full article here.